168 related articles for article (PubMed ID: 22906661)
21. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
22. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer.
Wang J; Thompson B; Ren C; Ittmann M; Kwabi-Addo B
Prostate; 2006 May; 66(6):613-24. PubMed ID: 16388505
[TBL] [Abstract][Full Text] [Related]
23. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Vanaja DK; Ballman KV; Morlan BW; Cheville JC; Neumann RM; Lieber MM; Tindall DJ; Young CY
Clin Cancer Res; 2006 Feb; 12(4):1128-36. PubMed ID: 16489065
[TBL] [Abstract][Full Text] [Related]
24. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
25. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
26. In silico analysis and DHPLC screening strategy identifies novel apoptotic gene targets of aberrant promoter hypermethylation in prostate cancer.
Murphy TM; Sullivan L; Lane C; O'Connor L; Barrett C; Hollywood D; Lynch T; Lawler M; Perry AS
Prostate; 2011 Jan; 71(1):1-17. PubMed ID: 20564325
[TBL] [Abstract][Full Text] [Related]
27. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha.
Moriyama-Gonda N; Shiina H; Terashima M; Satoh K; Igawa M
BJU Int; 2008 Feb; 101(4):485-91. PubMed ID: 17922863
[TBL] [Abstract][Full Text] [Related]
28. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer.
Dasari VK; Deng D; Perinchery G; Yeh CC; Dahiya R
J Urol; 2002 Jan; 167(1):335-8. PubMed ID: 11743352
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis.
Henrique R; Jerónimo C; Teixeira MR; Hoque MO; Carvalho AL; Pais I; Ribeiro FR; Oliveira J; Lopes C; Sidransky D
Mol Cancer Res; 2006 Jan; 4(1):1-8. PubMed ID: 16446401
[TBL] [Abstract][Full Text] [Related]
31. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer.
Jerónimo C; Henrique R; Oliveira J; Lobo F; Pais I; Teixeira MR; Lopes C
J Clin Pathol; 2004 Aug; 57(8):872-6. PubMed ID: 15280411
[TBL] [Abstract][Full Text] [Related]
32. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
Pakneshan P; Xing RH; Rabbani SA
FASEB J; 2003 Jun; 17(9):1081-8. PubMed ID: 12773490
[TBL] [Abstract][Full Text] [Related]
33. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic inactivation of PCDH10 in human prostate cancer cell lines.
Li Z; Li W; Xie J; Wang Y; Tang A; Li X; Ye J; Gui Y; Cai Z
Cell Biol Int; 2011 Jul; 35(7):671-6. PubMed ID: 21314642
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
[TBL] [Abstract][Full Text] [Related]
36. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
38. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
39. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
40. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
